Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03636152 · ClinicalTrials.gov registry record · Phase 2
Management of Cardiovascular Disease in Kidney Disease (MaCK) Study
A Phase 2 study, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
NCT03636152: Completed Phase 2 study, sponsored by VA Office of Research and Development.
NCT03636152 is a Phase 2 study that has completed, run by VA Office of Research and Development. The registered enrollment target is 100 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (25% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03636152, a Phase 2 study, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
Study Summary
Cardiovascular disease (CVD) is the largest concerns for patients with Chronic kidney disease (CKD). At present time the investigators do not have proven effective strategies to reduce high CVD related deaths in CKD. This study assesses a novel therapy (hydroxychloroquine, HCQ) for the treatment of CVD in patients with CKD. This is the first human proof-of-concept study and is planned to be conducted among US Veterans, who suffer from both CKD and CVD at a disproportionately greater rates. The outcome of this study has the potential to provide an entirely new line of therapy for the treatment of CVD in CKD.
Primary Outcome
Measurements of Carotid TPV at enrollment and serially over 18th months
Interventions
- DRUG Matching Placebo
- DRUG Hydroxychloroquine
- PROCEDURE MRI carotid
- PROCEDURE APWV
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2018-12-14 |
| Est. Completion | 2024-01-31 |
| Phase | Phase 2 |
What the finished NCT03636152 record still lists
NCT03636152 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (25% lower).
The record links to 0 conditions, and to 4 interventions - of which Matching Placebo is the first listed.
NCT03636152 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03636152 about?
NCT03636152 is a clinical study titled "Management of Cardiovascular Disease in Kidney Disease (MaCK) Study". Cardiovascular disease (CVD) is the largest concerns for patients with Chronic kidney disease (CKD). At present time the investigators do not have proven effective strategies to reduce high CVD related deaths in CKD. This study assesses a novel therapy (hydroxychloroquine, HCQ) for the treatment of ...
What is the current status of trial NCT03636152?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2018-12-14. Estimated completion is 2024-01-31.
What interventions are being tested in trial NCT03636152?
The interventions under investigation include: Matching Placebo (DRUG), Hydroxychloroquine (DRUG), MRI carotid (PROCEDURE), APWV (PROCEDURE).
Who is sponsoring clinical trial NCT03636152?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03636152's enrollment target sits among peer trials
100 672nd of 2000 higher than 1,263 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI